Skip to main content

Journals in Neuropharmacology

Comparative Biochemistry and Physiology - Part A: Molecular & Integrative Physiology

  • ISSN: 1095-6433
  • 5 Year impact factor: 2.2
  • Impact factor: 2.1
Comparative Biochemistry & Physiology (CBP) publishes papers in comparative, environmental and evolutionary physiology.Part A: Molecular and Integrative Physiology (CBPA), focuses on physiological systems, including behavior, circulation, development, excretion, ion regulation, endocrinology, locomotory, nervous, nutrition, respiration, and thermal biology. Most studies address regulatory mechanisms and span multiple levels of biological organization.All four CBP journals support and follow the editorial direction from all the major societies in the field:Australia & New Zealand Society of Comparative Physiology and Biochemistry (ANZSCPB)American Physiological Society (APS)Canadian Society of Zoologists (CSZ)Deutsche Zoologische Gesellschaft (DZG)European Society of Comparative Physiology and Biochemistry (ESCPB)Japanese Society for Comparative Physiology and Biochemistry (JSCPB)South American Society for Comparative Physiology and Biochemistry (SASCPB)Societe de Physiologie (SDP)Society for Experimental Biology (SEB)Society for Integrative & Comparative Biology (SICB)Benefits to authorsCBP journals are focused on promoting the authors and the work published in the journal:All articles are carefully evaluated directly by the Editors-in-Chief who are leading experts in their field.Availability: contact the Editor-in-Chief for any questions you may have.The Journal will provide upon request free PDFs to all authors who may not have access to their articles via their institution or library.Publication is free to authors (no color or page charges).Supporting open access: if your funding body or institution requires your article to be open access, CBP offers that option. Please see details here.Reuse figures from any CBP article via "get rights and content" hyperlink available within each article (below author names and affiliations) on ScienceDirect.Please click here for more information on more general author services.Other CBP journals Part B (CBPB): Biochemistry & Molecular Biology Part C (CBPC): Toxicology & Pharmacology Part D (CBPD): Genomics & Proteomics
Comparative Biochemistry and Physiology - Part A: Molecular & Integrative Physiology

Comparative Biochemistry and Physiology - Part D: Genomics and Proteomics

  • ISSN: 1744-117X
  • 5 Year impact factor: 2.5
  • Impact factor: 2.2
Comparative Biochemistry & Physiology (CBP) publishes papers in comparative, environmental and evolutionary physiology.Part D: Genomics and Proteomics (CBPD), focuses on “omics” approaches to physiology, including comparative and functional genomics, metagenomics, transcriptomics, proteomics, metabolomics, and lipidomics. Most studies employ “omics” and/or system biology to test specific hypotheses about molecular and biochemical mechanisms underlying physiological responses to the environment. We encourage papers that address fundamental questions in comparative physiology and biochemistry rather than studies with a focus that is purely technical, methodological or descriptive in nature.All four CBP journals support and follow the editorial direction from all the major societies in the field:Australia & New Zealand Society of Comparative Physiology and Biochemistry (ANZSCPB)American Physiological Society (APS)Canadian Society of Zoologists (CSZ)Deutsche Zoologische Gesellschaft (DZG)European Society of Comparative Physiology and Biochemistry (ESCPB)Japanese Society for Comparative Physiology and Biochemistry (JSCPB)South American Society for Comparative Physiology and Biochemistry (SASCPB)Societe de Physiologie (SDP)Society for Experimental Biology (SEB)Society for Integrative & Comparative Biology (SICB)Benefits to authorsCBP journals are focused on promoting the authors and the work published in the journal:All articles are carefully evaluated directly by the Editors-in-Chief who are leading experts in their field.Availability: contact the Editor-in-Chief for any questions you may have.The Journal will provide upon request free PDFs to all authors who may not have access to their articles via their institution or library.Publication is free to authors (no color or page charges).Supporting open access: if your funding body or institution requires your article to be open access, CBP offers that option. Please see details here.Reuse figures from any CBP article via "get rights and content" hyperlink available within each article (below author names and affiliations) on ScienceDirect.Please click here for more information on more general author services.Other CBP journals Part A (CBPA): Molecular & Integrative Physiology Part B (CBPB): Biochemistry & Molecular Biology Part C (CBPC): Toxicology & Pharmacology
Comparative Biochemistry and Physiology - Part D: Genomics and Proteomics

Epilepsy Research

  • ISSN: 0920-1211
  • 5 Year impact factor: 2.3
  • Impact factor: 2
Epilepsy Research provides for publication of high quality articles in both basic and clinical epilepsy research, with a special emphasis on translational research that ultimately relates to epilepsy as a human condition. The journal is intended to provide a forum for reporting the best and most rigorous epilepsy research from all disciplines ranging from biophysics and molecular biology to epidemiological and psychosocial research. As such the journal will publish original papers relevant to epilepsy from any scientific discipline and also studies of a multidisciplinary nature. Clinical and experimental research papers adopting fresh conceptual approaches to the study of epilepsy and its treatment are encouraged. The overriding criteria for publication are novelty, significant clinical or experimental relevance, and interest to a multidisciplinary audience in the broad arena of epilepsy. Review articles focused on any topic of epilepsy research will also be considered, but only if they present an exceptionally clear synthesis of current knowledge and future directions of a research area, based on a critical assessment of the available data or on hypotheses that are likely to stimulate more critical thinking and further advances in an area of epilepsy research.Benefits to authors We also provide many author benefits, such as Share Links, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: https://service.elsevier.com
Epilepsy Research

European Neuropsychopharmacology

  • ISSN: 0924-977X
  • 5 Year impact factor: 5.3
  • Impact factor: 6.1
An Official Journal of the European College of Neuropsychopharmacology European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.European Neuropsychopharmacology is the official journal of the European College of Neuropsychopharmacology (ECNP).Electronic usage: An increasing number of readers access the journal online via ScienceDirect, one of the world's most advanced web delivery systems for scientific, technical and medical information.Average monthly article downloads for this journal: 29,000
European Neuropsychopharmacology

Neuropharmacology

  • ISSN: 0028-3908
  • 5 Year impact factor: 4.5
  • Impact factor: 4.6
Neuropharmacology publishes high quality, original research within the discipline of neuroscience. The emphasis of Neuropharmacology is on the study and understanding of the actions of known exogenous and endogenous chemical agents on neurobiological processes in the mammalian nervous system. Work with non-mammalian and invertebrate species may be considered in exceptional circumstances. The journal does not usually accept clinical research, although neuropharmacological studies in humans may be considered on the condition that they provide novel insight into either the actions of drugs and/or neurobiological mechanisms. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Similarly, manuscripts describing the use of natural products will only be considered if the active ingredient is known and disclosed.The journal publishes Special Issues in which leading experts are invited to serve as Guest Editors to compile a collection of reviews, and occasionally original articles, around a particular topical theme in neuroscience research. The list of recent Special Issues can be found here. Suggestions for Special Issues can be made directly to the Editor-in-Chief.Neuropharmacology also publishes topical narrative reviews on subjects within its remit. These reviews are commissioned by the Editorial Team or arise after correspondence with potential authors. Unsolicited reviews will be considered, but authors are encouraged to contact the Editor-in-Chief of their intention to submit a review. Potential review authors should clearly indicate in the cover letter their expertise in the area, the timeliness of the topic, and how the review differs from, and adds to, recent published reviews on related topics. Authors are expected to have an established experimental track record in the topic of the review, and should provide full citations, including URLs/DOIs, of recent experimental papers in peer-reviewed journals relevant to the topic of the review in their cover letter. In the absence of an experimental track record, authors should provide a justification for why they believe they are the right persons to author this review article at this point in time. The absence of any such evidence of relevant experimental expertise or an explanation of author appropriateness will result in the return of the manuscript to the authors. On the basis of the case made by authors, potential overlap with planned Neuropharmacology content, and discussions with the Editorial Team, the Editor-in-Chief will provide authors with a prompt decision regarding the proposed review. Systematic reviews, meta- or bibliographic analyses will not be considered unless they are a necessary part of a Special Issue and conducted by experts in the field, and even then only under exceptional circumstances and at the discretion of the Editor-in-Chief.
Neuropharmacology

Neuroscience

  • ISSN: 0306-4522
  • 5 Year impact factor: 3
  • Impact factor: 2.9
Neuroscience is an international journal under the editorial direction of IBRO.Neuroscience publishes papers describing the results of original research on any aspect of the scientific study of the nervous system. Any paper, however short, will be considered for publication provided that it reports significant, new and carefully confirmed findings with full experimental details. Neuroscience is the sister journal of IBRO Neuroscience Reports
Neuroscience

Peptides

  • ISSN: 0196-9781
  • 5 Year impact factor: 2.9
  • Impact factor: 2.8
Peptides is an international journal presenting original contributions and reviews on the genetics, biochemistry, physiology, and pharmacology/pharmaceutics of biological active peptides, as well as their functions that relate to neuroscience, metabolic control, diabetes, clinical aspects in gastroenterology, endocrinology, diabetology, appetite control, cancer, and behavioral & psychological effects.Peptides emphasizes all aspects of high profile peptide research in mammals and non-mammalian vertebrates. Special consideration can be given to plants and invertebrates if related to peptides in general. Submission of articles with clinical relevance is particularly encouraged.
Peptides

Schizophrenia Research

  • ISSN: 0920-9964
  • 5 Year impact factor: 4
  • Impact factor: 3.6
An International Multidisciplinary Journal of the Schizophrenia International Research SocietyAs official journal of the Schizophrenia International Research Society (SIRS) Schizophrenia Research is THE journal of choice for international researchers and clinicians to share their work with the global schizophrenia research community. More than 6000 institutes have online or print (or both) access to this journal - the largest specialist journal in the field, with the largest readership!Schizophrenia Research's time to first decision is as fast as 6 weeks and its publishing speed is as fast as 4 weeks until online publication (corrected proof/Article in Press) after acceptance and 14 weeks from acceptance until publication in a printed issue.The journal publishes novel papers that really contribute to understanding the biology and treatment of schizophrenic disorders; Schizophrenia Research brings together biological, clinical and psychological research in order to stimulate the synthesis of findings from all disciplines involved in improving patient outcomes in schizophrenia.Manuscripts with a focus on cognition in schizophrenia can be submitted to the journal?s open access companion title, Schizophrenia Research: Cognition.
Schizophrenia Research